The selling is modest relative to market cap and likely part of routine portfolio management or 10b5-1 plans. The large grants suggest confidence in long-term retention, but no immediate bullish signal. Monitor for increased selling volume ahead of earnings or regulatory decisions.
Price Chart
Executive Summary
Jazz Pharmaceuticals insiders executed a mix of open-market sales and non-cash equity transactions over the past week. CEO and other executives received substantial stock awards, while two officers sold shares totaling $801K, consistent with recent insider selling trends.
Key Financial Metrics
Key Facts
- CEO Galá Renée D and other top executives were granted a total of 87,581 shares at $0 (non-cash awards), valued at ~$16.3M based on current stock price.
- Two insiders conducted open-market sales: COO Bruce Cozadd sold $587,843 worth of shares, and SVP Patricia Carr sold $213,243, totaling $801K in sales.
- Two insiders exercised derivatives: Patil Neena M exercised 20,125 shares ($2.28M value) and Norbert Riedel exercised 3,415 shares ($471K value), both likely part of pre-arranged plans.
- Total open-market selling represents 0.007% of Jazz's $11.5B market cap — well below the 0.1% threshold for materiality.
- No insider purchases were reported; all grants are non-cash compensation events, not economic transactions.
Financial Impact
$801,086 in open-market selling over 7 days, plus $2.75M in derivative exercises (non-cash). Stock awards represent $16.3M in compensation value but no immediate financial outflow.
Risk Factors
- Perception of insider profit-taking if selling accelerates ahead of key catalysts.
- Future dilution from exercised and awarded shares, though currently immaterial.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (11 trades, 7d window) | cluster-JAZZ-1772659526960 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 6d ago | Press Release | $213.76 $211.97 | ▼ −0.84% | ▼ −1.36% | $210.99 (−1.30%) |
Oct 9, 2026 17d ago | 8-K | $218.42 $216.75 | ▼ −0.76% | ▼ −0.70% | $210.99 (−3.40%) |
Oct 8, 2026 17d ago | 144 | $218.42 $216.75 | ▼ −0.76% | ▼ −0.70% | $210.99 (−3.40%) |
Oct 6, 2026 19d ago | 144 | $231.19 $222.45 | ▼ −3.78% | ▼ −3.36% | $210.99 (−8.74%) |
Oct 1, 2026 24d ago | 144 | $235.67 $236.04 | ▲ +0.16% | ▼ −0.52% | $210.99 (−10.47%) |
Sep 15, 2026 5w ago | 8-K | $240.83 $243.59 | ▲ +1.15% | ▲ +1.59% | $210.99 (−12.39%) |
Sep 14, 2026 5w ago | Insider Cluster | $240.83 $243.59 | ▲ +1.15% | ▲ +1.59% | $210.99 (−12.39%) |
Sep 10, 2026 6w ago | Insider Cluster | $245.80 $245.87 | ▲ +0.03% | ▲ +0.47% | $210.99 (−14.16%) |
Sep 2, 2026 7w ago | Insider Cluster | $247.57 $246.81 | ▲ +0.30% | ▼ −0.08% | $210.99 (+14.78%) |
Aug 31, 2026 7w ago | 144 | $243.71 $245.57 | ▲ +0.76% | ▲ +0.32% | $210.99 (−13.43%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers